Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 13/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30987170 | 0.83 | RORC (0.41) | RORCUSP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL30987027 | 0.83 | RORC (0.41) | RORCUSP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL30987087 | 0.83 | RORC (0.41) | RORCUSP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL28713613 | 0.83 | RORC (0.39) | RORCUSP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL25869829 | 0.83 | RORC (0.39) | RORCUSP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL30987153 | 0.81 | NR1H2 (0.42) | RORCUSP2SMN1; SMN2NR1H2MAPT | |
| SCHEMBL25869375 | 0.81 | RORC (0.39) | RORCUSP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL30987213 | 0.80 | RORC (0.39) | RORCUSP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL30987044 | 0.80 | RORC (0.35) | RORCUSP2SMN1; SMN2NR1H2MEN1 | |
| SCHEMBL25312447 | 0.80 | USP2 (0.40) | RORCUSP2SMN1; SMN2NR1H2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479837-B2 | Reversible DPP1 inhibitors and uses thereof | INSMED INCORPORATED (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4646265-A1 | NOVEL, REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | Insmed Incorporated (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250223284-A1 | REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED | 2025-07-10 | — | — | US | disclosed |
| WO-2024148308-A1 | NOVEL, REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | INSMED INCORPORATED (US) | 2024-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250223284-A1 | REVERSIBLE DPP1 INHIBITORS AND USES THEREOF | DPP4, DPP7, DPP9 | RORC 1203/4885USP2 2210/4885SMN1; SMN2 880/4885 |
| US-12479837-B2 | Reversible DPP1 inhibitors and uses thereof | DPP4, DPP7, DPP9 | RORC 1203/4885USP2 2210/4885SMN1; SMN2 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.